Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bamadutide (SAR425899) energy expenditure study in overweight/obese subjects
NCT03376802Phase 1Completed
- Sponsor
- Sanofi
- Start
- Apr 2018
- Primary completion
- Dec 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing SAR425899 with Placebo (2 arms). Primary endpoint: Sleep Energy Expenditure. Started Apr 2018; status: completed.
02
Drugs
bamadutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03376802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03376802.